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Despite multimodal therapy (the classical Stupp’s 
protocol) including surgical resection (as large as possible), 
radiotherapy and chemotherapy, glioblastoma (GBM) 
remain a burden as the global survival rate at two years 
reaches barely 9% of patients (1). This situation is mainly a 
consequence of a systematic recurrence and this recurrence 
is itself a consequence of various causes, acting alone or 
synergistically: heterogeneous nature of the disease (2), 
the presence of the brain-blood barrier which impedes the 
potentially active drugs to get into the brain (3), the lack of 
targeted chemotherapeutic molecules and the persistence of 
GBM-initiating or stem cells (GSC) (4).
The recent study of Calinescu et al. (5) specifically 
address the question of GSC as those cells have been 
demonstrated to be resistant to chemo- and radiotherapy 
(6,7) and responsible for promoting neo-angiogenesis in 
tumors (8). Indeed, the authors induced brain tumors in 
a model recently described and based on a plasmid which 
allow a knock-in of immature brain cells using a Sleeping 
Beauty transposase (9). The inserted genes are the simian 
virus 40 large T antigen (SV40-LgT) and a constitutively 
active human NRAS oncogene (NRAS). The plasmid 
construct was injected in the right lateral ventricle of post-
natal day 1 mice expressing the dsRed fluorescent protein 
under the control of the CXCL12 promoter. Ten days after 
the plasmid injection, one can observe clusters of cells in 
the sub-ventricular zone (SVZ) expressing the SV40-LgT, 
but also Nestin and Olig2, two markers of cell immaturity 
in the brain. These cell clusters are near capillary where 
endothelial cells express the chemokine CXCL12. Nineteen 
days after the plasmid injection, the tumors can be 
observed, some present in the SVZ and some in the brain 
parenchyma. Those tumors are surrounded by reactive 
astrocytes expressing high levels of GFAP. Those tumors 
express Nestin and Olig2 but also exhibit several GBM 
hallmarks (multinucleated cells, numerous mitosis, vascular 
proliferation, pseudopalisading necrosis). Moreover, there 
is a lack of an efficient brain-blood barrier as intravascular 
dextrans are able to diffuse into the tumor.
Those tumors have been put in cultures and Calinescu 
et al. demonstrated that some tumoral cells grown as 
spheres, express CD133 and are able to generate tumors 
when transplanted back in naïve mice. All these features are 
specificities of GSG. Therefore, the authors compare the 
transcriptome of those cells (named M7) to two other GBM 
established mouse cell lines (GL26 and GL26A1, the latter is 
overexpressing NRAS). They found a differential expression 
for 5866 probe sets, in which several chemokines: CCL2, 
CXCL1, CCL7 and CXCL12. They focused to CXCL12 
for two reasons: (I) they wanted to characterize the molecular 
environment of GSC that is responsible for the set-up of 
a niche for these tumor stem cells; and (II) CXCL12 has 
been previously shown to regulate neural and hematopoietic 
niches,  acting through its  CXCR4 receptor (10). 
Editorial
The CXCL12/CXCR4 pathway or the autocrine proliferative loop of 
the glioblastoma stem cells
Bernard Rogister1,2
1Laboratory of Nervous System Disorders and Therapy, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium; 2Department 
of Neurology, CHU and University of Liège, Liège, Belgium
Correspondence to: Bernard Rogister, MD, PhD. Laboratory of Nervous System Disorders and Therapy, GIGA-Neurosciences Research Center, 
University of Liège, Avenue Hippocrate, 15, 4000 Liège, Belgium. Email: Bernard.Rogister@ulg.ac.be.
Provenance: This is a Guest Editoral commissioned by the Section Editor Ning Huang (Department of Neurosurgery, The Second Affiliated Hospital 
of Chongqing Medical University, Chongqing, China).
Comment on: Calinescu AA, Yadav VN, Carballo E, et al. Survival and Proliferation of Neural Progenitor-Derived Glioblastomas Under Hypoxic 
Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism. Clin Cancer Res 2017;23:1250-62.
Submitted Feb 01, 2017. Accepted for publication Feb 08, 2017.
doi: 10.21037/tcr.2017.03.47
View this article at: http://dx.doi.org/10.21037/tcr.2017.03.47
3
2 Rogister. CXCL12/CXCR4 pathway and GBM growth
© Translational Cancer Research. All rights reserved.   Transl Cancer Res 2017 tcr.amegroups.com
Indeed, it appears that, at the phylogenetical point of view, 
the CXCL12/CXCR4 axis is very old, existing before the 
appearance of an adaptive immune response, with ancestral 
role in the nervous system (11).
Calinescu et al. quantified and characterized the 
expression of both CXCL12 and CXCR4 in their GBM 
model. They showed that the cytokine is expressed at high 
levels in the GBM induced by the transforming plasmid 
but also in the surrounding brain tissue. CXCR4, the 
CXCL12 receptor, is expressed at high level by tumoral 
cells, by immune infiltrating cells but not by normal brain 
cells. Finally, CXCR7, the other and less known CXCL12 
receptor, is barely detectable in the system. CXCL12 and 
CXCR4 are also expressed by cultivated tumoral cells and 
AMD3100 or Plerixafor, the classical CXCR4-inhibitor, 
stimulates in vitro the early apoptosis (modestly) and inhibits 
(more strongly) the cell proliferation. Indeed, cell cycle 
analysis revealed that AMD3100 maintains cells in G2/M 
phases and decreases the number of cells in S-phase. This 
could be a consequence of a decrease of expression of early 
G1 cyclins and CDKs like cyclin D1, CDK4 and CDK6.
Then, the authors looked for a possible action of 
AMD3100 on several pathways previously demonstrated to 
be important in GBM cells. They thus observed a decrease 
(I) of expression and of phosphorylation of the tumor 
suppressor retinoblastoma (Rb) which is over-activated 
by mutation or various alterations in 70% of GBM; (II) 
of phospho-Akt which is also over-activated in GBM 
cells both by various tyrosine-kinase receptors (EGFR, 
PDGFRA, VEGFR2, …) and by the inactivation of the 
phosphatase PTEN; (III) of the anti-apoptotic protein Bcl-
XL previously shown to be over-expressed in GBM. It 
is important to note that the effects of AMD3100 on the 
apoptosis of GBM cells, on their proliferation and on the 
down-regulation of all these proteins required a long (at 
least 72 hours) stimulation. 
CXCL12 is known to be overexpressed in hypoxic brain 
or by TGFβ (12). Calinescu et al. showed that in vitro, 
cxcl-12 is 6-fold overexpressed with an increase of hif1-α 
and tgf-β expression, at 96 hours of culture, while the cxr4 
expression remains stable. AMD3100 blocks the increase 
of expression of tgf-β and cxcl12 without any effect on the 
expression of hif1-α. These data suggest that the CXCL12/
CXCR4 pathway operated in GSC cultures as an autocrine 
positive feedback loop, promoting the survival and the 
proliferation of these cells.
As their GBM model is artificial (overexpression of 
SV40lgT and the mutated NRAS in post-natal mouse 
neural precursors), Calinescu et al. compared at the 
molecular level the spheres of GBM cells cultivated from 
their induced GBM and various GBM cells established in 
cell lines (U251 and U87) or derived from a gliosarcoma 
(which is a glioma with a high proportion of cells harboring 
mesenchymal features) and known to be enriched in GSC. 
Their comparisons were obtained by western blot and 
concerned some classical GBM markers. The authors 
conclude that there is a similar molecular profile between 
their induced-GBM cells and the human cells. However, a 
deeper molecular analysis, at the transcriptomic or at the 
proteomic level, would be useful here to assess the model 
used in the Calinescu’s paper.
This deeper molecular analysis between the induced-
GBM cells by the SV4LgT and NRAS and the other 
GBM cells, established as cell lines or derived from 
tumoral resection, is indeed mandatory as the expression of 
CXCL12 and CXCR4 but also the effect of a CXCL12- or 
an AMD3100-stimulation are various regarding other GBM 
cells tested by the authors.
Finally, Calinescu et al. treated by AMD3100 mice 
injected at post-natal day 1 with the transforming plasmid. 
The drug has been delivered by osmotic pumps that 
have been implanted at day 21 (when tumors develop 
macroscopically) and left in place for 5 days. The authors 
observe a non-significant tumor volume decrease when 
animals receive AMD3100 and a significant decrease of 
BrdU labeling index in the tumors. However, the median 
survival of AMD3100-treated animals was significantly 
higher (53 vs. 30 days) than animals that received saline. 
These results obtained with a pharmacological approach 
targeting the CXCR4 signalization were phenocopied using 
genetic approaches targeting the cxcr4 expression.
The merit of this study is  to demonstrate very 
conclusively the role of the CXCL12/CXCR4 pathway in 
a model of GBM growth and invasion. However, the first 
(but also the main) criticism that one can raise is in this 
interesting paper is about the model. Indeed, the model 
used by Calinescu et al. has the main advantages to be highly 
reproducible, to generate operationally-defined GSC and 
to produce tumors with all the histological characteristics 
described for GBM. The disadvantages of this model 
are the cell transformation of postnatal neural precursor, 
the relationship of the tumor with an immature brain 
parenchyma and, at least so far, a clear description of the 
molecular profiling of the tumors both, between themselves 
and with the human GBM. Indeed, it shouldn’t be now 
a big work to perform RNA sequencing assays of three to 
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six of these induced-GBM and to compare with themselves 
and with data available at the TCGA. This analysis could 
also be very instructive about the GBM subtype [with or 
without IDH mutations (13), the classification of those GBM 
according to Verhaak (14), …]. Concerning the age of the 
brain in which the GBM is induced, it could be important as 
in human patients, GBM in children and GBM in adult are 
different in their prognosis but also at a molecular level (15).
Finally, one can also have a regret. Indeed, in their 
model (with all the odds that we have explained), Calinescu 
et al. clearly demonstrated that the CXCL12/CXCR4 
pathway does play a role in tumor growth in vivo as the 
AMD3100 doubles the mice survival. It would have been 
interesting to look for a possible role of this signaling 
pathway in tumor arousal. One has to admit that implanting 
mini-osmotic pumps in newborn animals is technically 
difficult. However a targeted gene invalidation approach 
should be here very informative.
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